Halozyme Therapeutics (HALO) Interest Expenses (2011 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Interest Expenses data on file, last reported at $5.5 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 21.72% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a 66.59% decrease from a year earlier, with the FY2025 full-year figure at $18.1 million, changed 0.17% from the prior year.
• Interest Expenses for Q1 2026 stood at $5.5 million, up from -$8.4 million in the prior quarter.
• Over the last five years, Interest Expenses for HALO reached as high as $36.3 million in Q3 2025 and fell as low as -$8.4 million in Q4 2025.
• Historically, Interest Expenses has averaged $5.6 million across 5 years, with a median of $4.5 million in 2024.
• On a YoY basis, Interest Expenses climbed as much as 702.67% in 2025 and fell as far as 284.49% in 2025.
• Year by year, Interest Expenses stood at $4.6 million in 2022, then retreated by 18.84% to $3.7 million in 2023, then climbed by 22.4% to $4.5 million in 2024, then plunged by 284.49% to -$8.4 million in 2025, then soared by 165.76% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $5.5 million in Q1 2026, -$8.4 million in Q4 2025, and $36.3 million in Q3 2025.